Evan Ya-Wen Yu, MD, discusses the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between treatment with abiraterone and docetaxel for this population.
More From BioPortfolio on "Yu Shares Insight on Recent Advances in Castration-Sensitive Prostate Cancer"